X4 Pharmaceuticals beats revenue estimates, price target cut to USAlpha Vantage · Simply Wall St · · AI-summarised by FinFlash
X4 Pharmaceuticals reported quarterly revenue of US$2.9m, beating estimates by 25%, while posting a statutory loss of US$0.16 per share. Analysts reconfirmed 2027 revenue estimates of USUnderstand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
X4 Pharmaceuticals reported quarterly revenue of US$2.9m, beating estimates by 25%, while posting a statutory loss of US$0.16 per share. Analysts reconfirmed 2027 revenue estimates of US Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context